COVID-19-related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis.
作者信息
Blaize Marion, Mayaux Julien, Luyt Charles-Edouard, Lampros Alexandre, Fekkar Arnaud
机构信息
Groupe Hospitalier La Pitié-Salpêtrière Paris, France.
UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition Paris, France and.
出版信息
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1734-1736. doi: 10.1164/rccm.202007-2938LE.
Abstract
摘要
相似文献
1
COVID-19-related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis.
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1734-1736. doi: 10.1164/rccm.202007-2938LE.
2
Reply to Blaize : COVID-19-related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis.
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1736-1737. doi: 10.1164/rccm.202008-3174LE.
3
A Case of COVID-19 and Coinfection.
Am J Respir Crit Care Med. 2020 Jul 1;202(1):136-138. doi: 10.1164/rccm.202003-0766LE.
4
Pneumocystis jirovecii Pneumonia and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection in a Patient With Newly Diagnosed HIV-1 Infection.
Clin Infect Dis. 2021 Apr 26;72(8):1487-1489. doi: 10.1093/cid/ciaa906.
5
The presence of Pneumocystis jirovecii in critically ill patients with COVID-19.
J Infect. 2021 Apr;82(4):84-123. doi: 10.1016/j.jinf.2020.10.034. Epub 2020 Nov 4.
6
COVID-19 and Pulmonary Coinfection-The First Case Confirmed through Autopsy.
Medicina (Kaunas). 2021 Mar 24;57(4):302. doi: 10.3390/medicina57040302.
7
Pneumocystis pneumonia in the COVID-19 pandemic era: similarities and challenges.
Trends Parasitol. 2021 Oct;37(10):859-862. doi: 10.1016/j.pt.2021.07.010. Epub 2021 Aug 4.
8
Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity-Response to "Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19".
Crit Care. 2021 Dec 6;25(1):418. doi: 10.1186/s13054-021-03836-7.
9
Pneumocystis jirovecii and SARS-CoV-2 Coinfection as Presentation of X-linked Severe Combined Immunodeficiency.
Indian J Pediatr. 2023 Aug;90(8):832-833. doi: 10.1007/s12098-023-04661-2. Epub 2023 May 30.
10
An Unusual Case of Severe Pneumocystis Jiroveci Pneumonia (PJP) presenting as "Recurrent Cytokine Storm'' following COVID-19 Infection.
J Assoc Physicians India. 2021 May;69(5):78.
引用本文的文献
1
Post-COVID-19 severe pneumonia in a non-HIV and immunocompetent patient: A case report and literature review.
J Int Med Res. 2025 Jun;53(6):3000605251344140. doi: 10.1177/03000605251344140. Epub 2025 Jun 14.
2
Quantitative real time PCR for distinction between infection/colonization in hospitalized patients.
Front Cell Infect Microbiol. 2024 Sep 24;14:1426200. doi: 10.3389/fcimb.2024.1426200. eCollection 2024.
3
Trends in the Epidemiology of Pneumonia in Immunocompromised Patients without HIV Infection.
J Fungi (Basel). 2023 Jul 31;9(8):812. doi: 10.3390/jof9080812.
4
Molecular and microscopy detection of in hospitalized patients during the COVID-19 pandemic.
Front Med (Lausanne). 2023 Apr 6;10:1148320. doi: 10.3389/fmed.2023.1148320. eCollection 2023.
5
pneumonia in COVID-19 patients: A comprehensive review.
Heliyon. 2023 Feb;9(2):e13618. doi: 10.1016/j.heliyon.2023.e13618. Epub 2023 Feb 10.
6
Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic.
Microorganisms. 2022 Nov 10;10(11):2223. doi: 10.3390/microorganisms10112223.
7
Emerging and re-emerging fungal threats in Africa.
Parasite Immunol. 2023 Feb;45(2):e12953. doi: 10.1111/pim.12953. Epub 2022 Oct 17.
8
The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: A review.
Curr Res Biotechnol. 2022;4:337-349. doi: 10.1016/j.crbiot.2022.08.001. Epub 2022 Aug 3.
9
Concurrent Infection with SARS-CoV-2 and in Immunocompromised and Immunocompetent Individuals.
J Fungi (Basel). 2022 May 30;8(6):585. doi: 10.3390/jof8060585.
10
The first detection of Pneumocystis jirovecii in asthmatic patients post-COVID-19 in Jordan.
Bosn J Basic Med Sci. 2022 Sep 16;22(5):784-790. doi: 10.17305/bjbms.2022.7335.
本文引用的文献
1
A Case of COVID-19 and Coinfection.
Am J Respir Crit Care Med. 2020 Jul 1;202(1):136-138. doi: 10.1164/rccm.202003-0766LE.
2
Interpretation of CT signs of 2019 novel coronavirus (COVID-19) pneumonia.
Eur Radiol. 2020 Oct;30(10):5455-5462. doi: 10.1007/s00330-020-06915-5. Epub 2020 May 4.
3
Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State.
JAMA. 2020 Apr 28;323(16):1612-1614. doi: 10.1001/jama.2020.4326.
4
Therapy and Management of Infection.
J Fungi (Basel). 2018 Nov 22;4(4):127. doi: 10.3390/jof4040127.
5
Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia.
Clin Microbiol Infect. 2012 May;18(5):E122-7. doi: 10.1111/j.1469-0691.2012.03777.x. Epub 2012 Mar 8.
6
Kinetics of serum β-D-glucan after Pneumocystis pneumonia treatment in patients with AIDS.
Intern Med. 2011;50(13):1397-401. doi: 10.2169/internalmedicine.50.5296. Epub 2011 Jul 1.
7
Lymphocytes in host defense against Pneumocystis carinii.
Semin Respir Infect. 1998 Dec;13(4):330-8.
Zotero 插件